• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmaceutisch weekblad. >Losartan is kosteneffectief in de behandeling van hypertensie bij patienten met linkerventrikelhypertrofie
【24h】

Losartan is kosteneffectief in de behandeling van hypertensie bij patienten met linkerventrikelhypertrofie

机译：氯沙坦在左心室肥大患者的高血压治疗中具有成本效益

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Losartan is cost-effective in the treatment of hypertension in patients with left ventricular hypertrophy Objective The Losartan Intervention For Endpoint reduction (LIFE) study was a randomized, double-blind trial that compared the effects of losartan-based treatment with those of atenolol-based treatment on cardiovascular disease morbidity and mortality. The aim of the current study was to analyze the cost-effectiveness of losartan compared with atenolol in the prevention of stroke from the Dutch health care perspective. Design and methods Utilization of losartan and atenolol within the mean 4.8 years trial period and an estimation of direct medical costs of stroke for The Netherlands were combined with estimates of reduction in life expectancy through stroke. Medication costs and stroke incidence were estimated and to estimate lifetime stroke costs, the cumulative incidence of stroke was multiplied by the lifetime direct medical costs attributable to stroke. All costs are in 2006 Dutch prices and discounted following the Dutch pharmacoeconomic guideline (4% costs, 1.5% effects). Results Prevention of stroke was associated with a gain of 5.1 life-years. As a consequence, losartan treatment was associated with 0.081 life-years gained (LYG) per patient treated with losartan. Losartan reduced stroke-related costs by E 1076 per patient. After inclusion of study medication cost, net cost per patient was E 51 higher for losartan than for atenolol. The net cost per LYG was E 630 which is below the Dutch pharmacoeconomic threshold of E 20,000 per LYG. The probability of a cost-effectiveness ratio below this threshold was 0.97. Conclusion Results from the present analysis suggest that, in The Netherlands, treatment with losartan compared with atenolol may well be a cost-effective intervention.
机译：摘要氯沙坦在左心室肥厚患者的高血压治疗中具有成本效益。目的氯沙坦终点干预（LIFE）研究是一项随机，双盲试验，比较了以氯沙坦为基础的治疗与阿替洛尔治疗的效果。根据心血管疾病的发病率和死亡率进行治疗。本研究的目的是从荷兰卫生保健的角度分析氯沙坦与阿替洛尔相比在预防中风方面的成本效益。设计与方法在平均4.8年的试用期内使用氯沙坦和阿替洛尔，以及对荷兰中风的直接医疗费用进行估算，并结合中风导致的预期寿命降低进行估算。估计了药物成本和中风发生率，并估算了终生中风成本，将中风的累积发生率乘以可归因于中风的终生直接医疗费用。所有费用均以2006年荷兰的价格为准，并按照荷兰的药物经济学指南进行了折现（费用为4％，影响为1.5％）。结果预防中风可增加5.1个生命年。结果，氯沙坦治疗与每位接受氯沙坦治疗的患者的0.081生命年（LYG）相关。氯沙坦使每位患者的中风相关费用降低了1076 E。计入研究药物的成本后，氯沙坦的每位患者的净成本比阿替洛尔高出E 51。每个LYG的净成本为E 630，低于荷兰药理学阈值每LYG 20,000E。成本效益比低于此阈值的可能性为0.97。结论目前的分析结果表明，在荷兰，氯沙坦与阿替洛尔相比可能是一种经济有效的干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号